Yabusaki N, Komatsu H, Tago K, Yamada Y, Ueno A
Department of Urology, Yamanashi Medical College.
Nihon Hinyokika Gakkai Zasshi. 1991 Feb;82(2):290-6. doi: 10.5980/jpnjurol1989.82.290.
The efficacy of maintenance bacillus Calmette-Guerin (BCG) instillations for superficial bladder tumors was studied by prospective randomized trial. From June 1985 to October 1988, 42 newly diagnosed patients with superficial bladder carcinoma (pTa or pT1) were treated by transurethral tumor resection and subsequent five daily instillations of mitomycin C. Then they were divided into non-maintenance group (22 patients) and maintenance group (20 patients) by randomization. The patients received six weekly instillations of 80 mg of BCG. Tokyo strain (Japan BCG manufacturing Co., Tokyo, Japan), suspended in 40 ml of physiological saline, and the patients in the maintenance group received four additional instillations of BCG every three months. We could not complete the six-week course of BCG instillations in three patients due to adverse effects (two in non-maintenance group and one in maintenance group) and we lost six patients from follow-up within one year (one in non-maintenance group and five in maintenance group). The mean follow-up period of the remaining 33 patients was 28.1 months. Of these 33 patients, six patients had been found to have recurrent tumors, and the over-all three-year non-recurrence rate was 82%. Before employing BCG, when we used only mitomycin C after TUR-Bt, the three year non-recurrence rate was 58%. This indicates prophylactic effect of BCG instillations. The stage of the initial tumor of the six recurrent cases were all pT1b. The non-recurrence rate of the patients with pT1b tumor was significantly lower than that of the patients with pTa and pT1a tumor. However, multiplicity and grade of tumors did not affect the non-recurrence rate.(ABSTRACT TRUNCATED AT 250 WORDS)
通过前瞻性随机试验研究了维持性卡介苗(BCG)膀胱灌注治疗浅表性膀胱肿瘤的疗效。1985年6月至1988年10月,42例新诊断的浅表性膀胱癌(pTa或pT1)患者接受了经尿道肿瘤切除术,随后每日5次膀胱灌注丝裂霉素C。然后将他们随机分为非维持组(22例患者)和维持组(20例患者)。患者接受每周1次、每次80mg卡介苗东京株(日本东京BCG制造公司)膀胱灌注,悬浮于40ml生理盐水中,维持组患者每3个月额外接受4次卡介苗灌注。由于不良反应(非维持组2例,维持组1例),3例患者未能完成6周的卡介苗灌注疗程,1年内失访6例(非维持组1例,维持组5例)。其余33例患者的平均随访期为28.1个月。在这33例患者中,6例发现有肿瘤复发,总体三年无复发率为82%。在使用卡介苗之前,我们在经尿道膀胱肿瘤电切术后仅使用丝裂霉素C时,三年无复发率为58%。这表明卡介苗灌注具有预防作用。6例复发患者的初始肿瘤分期均为pT1b。pT1b期肿瘤患者的无复发率显著低于pTa和pT1a期肿瘤患者。然而,肿瘤的多发性和分级并不影响无复发率。(摘要截短于250字)